Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1).

Saved in:
Bibliographic Details
Title: Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1).
Authors: Ri M; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan. rrmasaki@med.nagoya-cu.ac.jp., Iida S; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan., Saito K; Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan., Saito Y; Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan., Maruyama D; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Asano A; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan., Fukuhara S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan., Tsujimura H; Department of Hematology and Medical Oncology, Chiba Cancer Center, Chiba, Japan., Miyazaki K; Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan., Ota S; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan., Fukuhara N; Department of Hematology, Tohoku University Hospital, Sendai, Japan., Negoro E; Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan., Kuroda J; Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan., Yoshida S; Department of Hematology, NHO Nagasaki Medical Center, Nagasaki, Japan., Ohtsuka E; Department of Hematology, Oita Prefectural Hospital, Oita, Japan., Norifumi T; Department of Hematology, Gunma University, Maebashi, Japan., Tabayashi T; Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan., Takayama N; Department of Hematology, Kyorin University Faculty of Medicine, Mitaka, Japan., Saito T; Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan., Suzuki Y; Department of Hematology, NHO Nagoya Medical Center, Nagoya, Japan., Harada Y; Department of Hematology, Toyota Kosei Hospital, Toyota, Japan., Mizuno I; Division of Hematology, Hyogo Cancer Center, Akashi, Japan., Yoshida I; Department of Hematologic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan., Maruta M; Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Matsuyama, Japan., Takamatsu Y; Division of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan., Katsuya H; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan., Yoshimitsu M; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan., Minami Y; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan., Kanato K; JCOG Data Center/Operating Office, National Cancer Center Hospital, Tokyo, Japan., Munakata W; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan., Nagai H; Department of Hematology, NHO Nagoya Medical Center, Nagoya, Japan.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Jan 24; Vol. 95 (1), pp. 29. Date of Electronic Publication: 2025 Jan 24.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1432-0843
DOI:10.1007/s00280-025-04752-1